CEP-1347 10mg
C1347c/204/PD/US-CA
Phase 3 small_molecule terminated
Quick answer
CEP-1347 10mg for Parkinson Disease is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Parkinson Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated